Contribution of marrow-derived progenitors to vascular and cardiac regeneration

Rafii, Shahin; Meeus, Sarah; Dias, Sérgio; Hattori, Koichi; Heissig, Beate; Shmelkov, Sergey V.; Rafii, Daniel C.; Lyden, David

doi:10.1006/scdb.2001.0285

Cited by 138 publications

(71 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The importance of endothelial progenitor cells to the generation of vasculature in ischemic cardiac tissues is being investigated. 1,32 One recent clinical study showed that transplantation of bone marrow-derived CD133 ϩ cells improves the function of infarcted myocardium. 33 The authors proposed that angiogenesis was the key factor in this process, although the precise mechanisms were not investigated.…”

Section: Circulating Cd133mentioning

confidence: 99%

Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133 ⁺ Stem Cells Into Angiomyogenic Tissue

et al. 2005

Self Cite

View full text Add to dashboard Cite

Background-CD133 (AC133) is a surface antigen that defines a broad population of stem cells, including myogenic and endothelial progenitors. CD133 ϩ cells are rare in adult tissues, and the factors that support their differentiation into mature angiomyogenic cells are not known. These hurdles have hampered the use of CD133 ϩ cells for therapeutic purposes. Because human fetal liver is a rich source of CD133 ϩ cells, we sought to identify the growth factors that promote codifferentiation of these cells into angiogenic and myogenic cells. Methods and Results-Human fetal liver CD133ϩ and CD133 Ϫ cell subpopulations were cultured with 5Ј-azacytidine or vascular endothelial growth factor (VEGF 165 ) and/or brain-derived nerve growth factor (BDNF

show abstract

Section: Circulating Cd133mentioning

confidence: 99%

Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133 ⁺ Stem Cells Into Angiomyogenic Tissue

et al. 2005

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mice were rescued by i.v. administration of 2-5 ϫ 10 6 unfractionated BM cells 24 h after irradiation (13,20,21). BM cells were obtained aseptically by flushing femur, tibia, and humerus of ROSA26 or COL4A3 Ϫ/Ϫ donor mice (13,20,21).…”

Section: Methodsmentioning

confidence: 99%

Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease

Sugimoto

Mundel

Sund

et al. 2006

Proc. Natl. Acad. Sci. U.S.A.

228

174

View full text Add to dashboard Cite

Type IV collagen is a predominant component of basement membranes, and glomeruli of a kidney filter Ϸ70 -90 liters of plasma every day through a specialized glomerular basement membrane (GBM). In Alport syndrome, a progressive disease primarily affecting kidneys, mutations in GBM-associated type IV collagen genes (COL4A3, COL4A4, or COL4A5) lead to basement membrane structural defects, proteinuria, renal failure, and an absence of all three GBM collagen triple helical chains because of obligatory posttranslational assembly requirements. Here, we demonstrate that transplantation of wild-type bone marrow (BM) into irradiated COL4A3 ؊/؊ mice results in a possible recruitment of BM-derived progenitor cells as epithelial cells (podocytes) and mesangial cells within the damaged glomerulus, leading to a partial restoration of expression of the type IV collagen ␣3 chain with concomitant emergence of ␣4 and ␣5 chain expression, improved glomerular architecture associated with a significant reduction in proteinuria, and improvement in overall kidney histology compared with untreated COL4A3 ؊/؊ mice or irradiated COL4A3 ؊/؊ mice with BM from adult COL4A3 ؊/؊ mice. The ␣3(IV) collagen produced by BM-derived podocytes integrates into the GBM and associates with other ␣-chains to form type IV collagen triple helical networks. This study demonstrates that BM-derived stem cells can offer a viable strategy for repairing basement membrane defects and conferring therapeutic benefit for patients with Alport syndrome.Alport syndrome ͉ bone marrow transplantation ͉ glomerular basement membrane ͉ type IV collogen ␣3 chain ͉ glomeruli

show abstract

“…28 Nevertheless, it is important to emphasize that at the doses used to treat myeloproliferative disorders, HC rarely shows acute toxicity and generally has been reported to be well tolerated. 29,30 This low toxicity in vivo does not rule out the possibility that more subtle effects associated with progenitor cell depletion or disruption of tissue repair mechanisms, in which bone marrow stem cells are now known to be involved, 31 may occur in the longer term.…”

Section: Discussionmentioning

confidence: 99%

Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage

et al. 2006

View full text Add to dashboard Cite

Anagrelide (ANA) and hydroxycarbamide (HC) are two distinct pharmacological agents used to treat thrombocythaemia associated with myeloproliferative disorders. Although both drugs have been in clinical use for a number of years, comparative studies of their selectivity and mode of action are still lacking. Here, we have evaluated the activities of ANA and HC on the growth and differentiation of human haematopoietic progenitor cells in liquid culture. Both drugs inhibited thrombopoietininduced megakaryocytopoiesis in a dose-dependent manner, but with strikingly different potencies (IC 50 ¼ 26 nM for ANA and 30 lM for HC) and modes of action. Whereas HC inhibited cell proliferation, ANA acted primarily on the differentiation process. At doses that abrogated megakaryocytopoiesis, HC also inhibited the expansion of CD34 þ cells stimulated by stem cell factor, interleukin-3 and Flt-3 ligand and also induced apoptosis. Furthermore, HC inhibited erythroid and myelomonocytic cell growth, induced by erythropoietin or granulocyte-macrophage colony-stimulating factor, respectively. In contrast, ANA showed none of these additional effects. Taken together, these results demonstrate that ANA is a potent and selective inhibitor of megakaryocytopoiesis, having no significant activity against haematopoietic progenitor cell expansion or differentiation into other lineages. In contrast, the anti-megakaryocytopoietic activity of HC cannot be dissociated from its more general cytoreductive and cytotoxic actions.

show abstract

Contribution of marrow-derived progenitors to vascular and cardiac regeneration

Cited by 138 publications

References 41 publications

Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133 ⁺ Stem Cells Into Angiomyogenic Tissue

Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133 ⁺ Stem Cells Into Angiomyogenic Tissue

Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease

Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage

Contact Info

Product

Resources

About

Contribution of marrow-derived progenitors to vascular and cardiac regeneration

Cited by 138 publications

References 41 publications

Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133 + Stem Cells Into Angiomyogenic Tissue

Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133 + Stem Cells Into Angiomyogenic Tissue

Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease

Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage

Contact Info

Product

Resources

About

Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133 ⁺ Stem Cells Into Angiomyogenic Tissue

Cytokine Preconditioning Promotes Codifferentiation of Human Fetal Liver CD133 ⁺ Stem Cells Into Angiomyogenic Tissue